General Atomics Awarded U.S. Space Force Contract for Phase 2 of the Enterprise Space Terminal Program
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 8, 2025 / General Atomics Electromagnetic Systems (GA-EMS) announced today that it has been awarded a contract by the U.S. Space Force (USSF) Space Systems Command (SSC) for Phase 2 of the Enterprise Space Terminal (EST) program. This Phase 2 contract award was issued through the Space Enterprise Consortium (SpEC) via an Other Transaction Agreement (OTA). The EST program is an enterprise optical communications solution to enhance mission effectiveness by providing resilient, high-capacity communication solutions for Department of Defense (DoD) space platforms operating primarily in beyond Low Earth Orbit (bLEO) regimes at crosslink ranges from 10,000 to 80,000 kilometers while maintaining the ability to operate in the LEO regime.
"GA-EMS, under a Phase 1 contract award, leveraged its extensive Optical Communication Terminal (OCT) expertise to develop a design that can be efficiently scaled to deploy a mesh network enterprise of OCTs with capabilities to transfer large volumes of data between spacecraft and ground stations distributed across a wide spectrum of operational domains," said Scott Forney, president of GA-EMS. "We are excited to enter Phase 2 to advance our system design and begin the build and test of the OCT subsystems."
Phase 2 will include lab demonstrations of OCT subsystems within a government provided test bed. GA-EMS will continue design and analyses activities to optimize the system designs. Testing results and analyses will then be presented during a Critical Design Review (CDR) at the end of Phase 2 period of performance.
"The Phase 2 CDR will help inform the decision gate toward entering Phase 3 of the program, which will call for the assembly, test, and delivery of an integrated prototype OCT system for demonstration on a government provided test bed," said Gregg Burgess, vice president of GA-EMS Space Systems. "We look forward to delivering a robust, producible Optical Communication Terminal for the Space Force to ensure resilient space network connectivity for future National Security Space Architectures."
GA-EMS completed the preliminary design of the payload support system, electrical hardware, laser terminal design, optical design and subsystem, thermal control, and command and data handling under the EST Phase 1 contract awarded in 2024. As prime contractor, GA-EMS has teamed with L3Harris for the modem subsystem and Advanced Space to provide performance modelling.
SOURCE: General Atomics Electromagnetic Systems
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
34 minutes ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Indianapolis Star
4 hours ago
- Indianapolis Star
Divorced and Facing IRS Collection? Clear Start Tax Outlines How Innocent Spouse Relief Could Save You Thousands
Clear Start Tax Explains How Divorced Taxpayers Can Escape IRS Liability for a Former Spouse's Mistakes IRVINE, CA / ACCESS Newswire Divorce can be complicated enough without the added stress of IRS debt. Yet every year, countless divorced Americans are shocked to discover they're on the hook for a former spouse's tax liabilities – often for mistakes they didn't know about. According to Clear Start Tax, a leading national tax resolution firm, the IRS's Innocent Spouse Relief program can offer a powerful – and often overlooked – solution. When Divorce Leaves Taxpayers Facing a Former Spouse's Mistakes Many taxpayers assume that a divorce decree automatically separates their financial obligations. But under joint tax returns, the IRS can pursue either spouse for the full amount owed, including taxes, penalties, and interest. That means years after a divorce, one spouse may face wage garnishment, bank levies, or collection notices for a tax bill they had no role in creating. 'We've worked with clients blindsided by IRS letters years after their divorce,' said the Head of Client Solutions at Clear Start Tax. 'Innocent Spouse Relief can be a lifeline in these cases – but most people don't even realize it exists.' Who Qualifies for Innocent Spouse Relief? Clear Start Tax explains that the IRS looks at several key factors when reviewing Innocent Spouse claims: The tax understatement was due to the other spouse's error (such as unreported income or inflated deductions). The innocent spouse didn't know, and had no reason to know, about the issue at the time. Holding the innocent spouse liable would be unfair or create hardship. The innocent spouse applies within the IRS's filing window (generally two years from first collection notice). Why the Right Approach Is Essential for Approval While the program offers powerful protection, Clear Start Tax emphasizes that success depends on a careful application and thorough documentation. Missing deadlines, submitting incomplete paperwork, or misunderstanding eligibility rules can lead to denial, leaving taxpayers exposed to the full debt. 'Innocent Spouse Relief isn't just a form-it's a carefully built case,' said the Head of Client Solutions at Clear Start Tax. 'We work closely with our clients to present the strongest possible application, so they can move forward without being burdened by a former partner's tax mistakes.' How Clear Start Tax Helps Divorced Taxpayers Regain Control Clear Start Tax offers a hands-on, strategic approach to Innocent Spouse claims and other tax resolution programs: Comprehensive case reviews to assess eligibility and strengthen claims Detailed preparation of IRS applications with supporting evidence Direct IRS communication and negotiation on the client's behalf Post-resolution guidance to maintain compliance and peace of mind About Clear Start Tax Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm's unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry. Need Help With Back Taxes? Click the link below: Contact Information Clear Start Tax Corporate Communications Department seo@ (949) 535-1627 SOURCE: Clear Start Tax View the original press release on ACCESS Newswire
Yahoo
4 hours ago
- Yahoo
Trading Technologies' TT® platform wins award for Best Derivatives Trading System in Markets Media's 2025 Global Markets Choice Awards
Win follows Best in Fintech recognition for Alice Pocklington, EVP Head of APAC, in Markets Media 2025 Women in Finance Asia Awards CHICAGO and NEW YORK, June 6, 2025 /PRNewswire/ -- Trading Technologies International, Inc. (TT), a global capital markets technology platform services provider, today announced that its TT platform won the award for Best Derivatives Trading System in Markets Media Group's 2025 Global Markets Choice Awards. The awards were presented last night at an event in New York. Alun Green, TT's EVP Managing Director, Futures & Options, said: "As we continue to build on our significant expansion into new asset classes and services across the trade life cycle, it remains a high honor to receive recognition for excellence in support of derivatives trading, which will always be an important focus for TT. Thanks to Markets Media for continually celebrating the best the industry has to offer." Terry Flanagan, Managing Director, Markets Media, said: "Trading Technologies has a longstanding market-leading position as a platform of choice for sophisticated traders of futures and options on futures. And it's not standing still — the firm continues to add functionalities and raise the bar on algorithmic execution and multi-asset digitization, and it has recently added support for U.S. equity options. Trading Technologies is a logical winner for Best Derivatives Trading System." The award is the second recent recognition for TT from Markets Media. Last week, Alice Pocklington, TT EVP Head of APAC, won Markets Media's 2025 Women in Finance Asia Award for Best in Fintech, presented at an event in Singapore. The awards celebrate "the most dynamic, talented and accomplished professional women who drive excellence in the financial centers of Hong Kong, Singapore, Tokyo and Sydney." The TT platform offers multi-asset solutions across the trade life cycle. The platform, which handled more than 2.8 billion derivatives transactions alone in 2024, includes a comprehensive order and execution management system (O/EMS) connecting to more than 100 global exchanges and venues across asset classes. Traditionally a North American award, the Markets Choice Awards are now global as of this year. The awards recognize and celebrate the "best of the best in capital markets trading and technology." In 2024, TT won the Markets Media European Markets Choice Award for Best Listed Derivatives Exchange/Order Management System (E/OMS). About Trading Technologies Trading Technologies ( is a global capital markets platform services company providing market-leading technology for the end-to-end trading operations of Tier 1 banks, brokerages, money managers, hedge funds, proprietary traders, Commodity Trading Advisors (CTAs), commercial hedgers and risk managers. With its roots in listed derivatives, the Software-as-a-Service (SaaS) company delivers "multi-X" solutions, with "X" representing asset classes, functions, workflows and geographies. This multi-X approach features trade execution services across futures and options, fixed income, foreign exchange (FX) and cryptocurrencies augmented by solutions for data and analytics, including transaction cost analysis (TCA); quantitative trading; compliance and trade surveillance; clearing and post-trade allocation; and infrastructure services. The award-winning TT platform ecosystem also helps exchanges deliver innovative solutions to their market participants, and technology companies to distribute their complementary offerings to Trading Technologies' clients. View original content to download multimedia: SOURCE Trading Technologies Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
